Drug Information

Drug (ID: DG01902) and It's Reported Resistant Information

• Name: ALRN-6924
• Synonyms: ALRN-6924
• Indication:
  In total 4 Indication(s)
  Acute myeloid leukaemia [ICD-11: 2A60]; Phase 1; [1]
  Haematological malignancy [ICD-11: 2B33]; Phase 1; [1]
  Myelodysplastic syndrome [ICD-11: 2A37]; Phase 2; [1]
  Solid tumour/cancer [ICD-11: 2A00-2F9Z]; Phase 2; [1]
• Drug Resistance Disease(s):
  Disease(s) with Clinically Reported Resistance for This Drug (1 diseases)
  Acute myeloid leukemia [ICD-11: 2A60]; [1]
• Target: Ubiquitin-protein ligase E3 Mdm2 (MDM2); MDM2_HUMAN; [1]

Type(s) of Resistant Mechanism of This Drug

  UAPP: Unusual Activation of Pro-survival Pathway

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Acute myeloid leukemia [ICD-11: 2A60]

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Unusual Activation of Pro-survival Pathway (UAPP)

Key Molecule: Cellular tumor antigen p53 (TP53) [1]

• Molecule Alteration: Missense mutation; p.R248Q (c.743G>A)
• Resistant Disease: Acute myeloid leukemia [ICD-11: 2A60.0]
• Experimental Note: Identified from the Human Clinical Data

References

• Ref 1: Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemiaSci Transl Med. 2018 Apr 11;10(436):eaao3003. doi: 10.1126/scitranslmed.aao3003.